PriceTargets.com logo

Scribe Therapeutics - SCTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $51.75
  • Forecasted Upside: 208.22%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$16.79 As of 10/2/2026 05:00 PM ET
▼ -0.38 (-2.21%)

This chart shows the closing price for SCTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Scribe Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCTX

Analyst Price Target is $51.75
▲ +208.22% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Scribe Therapeutics in the last 3 months. The average price target is $51.75, with a high forecast of $60.00 and a low forecast of $37.00. The average price target represents a 208.22% upside from the last price of $16.79.

This chart shows the closing price for SCTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Scribe Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/11/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/1/2026Zacks ResearchUpgradeHold
8/31/2026HC WainwrightInitiated CoverageBuy ➝ Buy$60.00
8/18/2026GuggenheimInitiated CoverageBuy$50.00
8/18/2026Wells Fargo & CompanyInitiated CoverageOverweight$60.00
8/18/2026Wells Fargo & CompanyInitiated CoverageOverweight$60.00
8/18/2026GuggenheimInitiated CoverageBuy$50.00
8/18/2026Leerink PartnersInitiated CoverageOutperform$37.00
(Data available from 10/3/2021 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/4/2026
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2026
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/3/2026

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Scribe Therapeutics logo
Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc. is based in ALAMEDA, Calif.
Read More

Today's Range

Now: $16.79
Low: $16.49
High: $17.81

50 Day Range

MA: $26.12
Low: $16.79
High: $37.25

52 Week Range

Now: $16.79
Low: $16.49
High: $39.60

Volume

473,941 shs

Average Volume

474,145 shs

Market Capitalization

$317.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Scribe Therapeutics?

The following Wall Street sell-side analysts have issued reports on Scribe Therapeutics in the last year: Guggenheim, HC Wainwright, Leerink Partners, Wall Street Zen, Wells Fargo & Company, and Zacks Research.
View the latest analyst ratings for SCTX.

What is the current price target for Scribe Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Scribe Therapeutics in the last year. Their average twelve-month price target is $51.75, suggesting a possible upside of 208.2%. Wells Fargo & Company has the highest price target set, predicting SCTX will reach $60.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $37.00 for Scribe Therapeutics in the next year.
View the latest price targets for SCTX.

What is the current consensus analyst rating for Scribe Therapeutics?

Scribe Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SCTX.

How do I contact Scribe Therapeutics' investor relations team?

Scribe Therapeutics' physical mailing address is 1150 Marina Village Pkwy, Alameda, CA, 94501. The company's listed phone number is (510) 454-0213 and its investor relations email address is [email protected]. The official website for Scribe Therapeutics is www.scribetx.com. Learn More about contacing Scribe Therapeutics investor relations.